Close
10/02/2016
New mechanism of anti-tumour action for the new drug developped at the UAB
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park, Barcelona Synchrotron Park partner), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.

The study, which has been published in the prestigious journal Clinical Cancer Research, was coordinated by Dr José Miguel Lizcano from the UAB Institute of Neurosciences and Department of Biochemistry and Molecular Biology.

Through the newly identified mechanism, ABTL0812 attacks tumour cells without affecting healthy cells, causing their death by autophagy without activating apoptosis (programmed cell death). It is the first anti-tumour drug to act in this way.

ABTL0812 has recently undergone Clinical Phase I trials in patients with advanced cancer, showing efficacy in several patients (long term stabilization) as well as low toxicity and high tolerability. Clinical Phase II trials are due to start soon in patients with endometrial cancer and lung squamous cell carcinoma.

More news

11/03/2015 Sustainability: the Barcelona Synchrotron Park focuses on birds and bats… 05/03/2015 Wastewater that produces green energy 26/02/2015 ALBA, CSIC and Alibava develop an X-Ray detector 20/02/2015 The pressure that makes conductivity higher: new record in the ICN2 11/02/2015 Presentation of the Big Data CoE Barcelona initiative 06/02/2015 Come investigate at the ALBA synchrotron: 2015 new call for proposals
34 35 36 37 38 39 40 41 42 43 44